Rhythm forced to wait for Imcivree expansion as FDA delays decision
The US Food and Drug Administration (FDA) has extended the review period for expanded approval of Rhythm Pharmaceuticals’ Imcivree (setmelanotide)…
Metabolic Disorders
-
-
Trump hits long-term pledge as US prices of weight loss drugs slashed
President Donald Trump achieved one of his key targets in the healthcare sector, following agreements with Eli Lilly and Novo…
-
Novo Nordisk’s oral Wegovy reduces cardiovascular risk factors in obesity
Novo Nordisk’s oral therapy Wegovy (semaglutide) reduced cardiovascular risk factors in the Phase III OASIS 4 trial. Being used by…
-
Novo Nordisk and Pfizer’s bidding war for Metsera escalates despite legal threats
Novo Nordisk has raised its offer to buy out obesity biotech Metsera to $10bn as a bidding war with Pfizer…
-
Eli Lilly ramps up orforglipron production with $1.2bn Puerto Rico site expansion
Eli Lilly will invest more than $1.2bn into its manufacturing site in Puerto Rico, as the drugmaker looks to assemble…
-
GLP-1RA microdosing trend continues despite “anecdotal evidence”
Found Health has become the latest telehealth company to offer a microdosing programme with weight loss jabs, despite an absence…
-
Kailera nets $600m to power Phase III launch of obesity drug
Just a year after emerging from stealth with a nearly half a billion dollars, Kailera Therapeutics has reached another financing…
-
Novo Nordisk buys MASH specialist Akero for up to $5.2bn
Novo Nordisk has agreed to buy Akero Therapeutics in a deal rising to a potential $5.2bn, as the Danish drugmaker…
-
Can oral GLP-1RAs deliver on the promise of accessible obesity care?
As the race for oral glucagon-like peptide-1 receptor agonists (GLP-1RA) intensifies, physicians hope that their small molecule format will make…
-
Pfizer buys monthly GLP-1RA developer Metsera for $4.9bn
Pfizer has acquired Metsera for $4.9bn, as the drugmaker targets longer-lasting glucagon-like peptide-1 receptor agonists (GLP-1RAs) to cement market share…
